HEMISPHERE ENERGY CORP (HME.CA) Fundamental Analysis & Valuation

TSX-V:HMECA4236301020

Current stock price

2.84 CAD
+0.02 (+0.71%)
Last:

This HME.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. HME.CA Profitability Analysis

1.1 Basic Checks

  • In the past year HME was profitable.
  • HME had a positive operating cash flow in the past year.
  • Of the past 5 years HME 4 years were profitable.
  • In the past 5 years HME always reported a positive cash flow from operatings.
HME.CA Yearly Net Income VS EBIT VS OCF VS FCFHME.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

  • HME's Return On Assets of 24.66% is amongst the best of the industry. HME outperforms 98.10% of its industry peers.
  • HME's Return On Equity of 38.33% is amongst the best of the industry. HME outperforms 98.57% of its industry peers.
  • HME's Return On Invested Capital of 31.98% is amongst the best of the industry. HME outperforms 99.52% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HME is significantly above the industry average of 6.90%.
  • The last Return On Invested Capital (31.98%) for HME is well below the 3 year average (38.31%), which needs to be investigated, but indicates that HME had better years and this may not be a problem.
Industry RankSector Rank
ROA 24.66%
ROE 38.33%
ROIC 31.98%
ROA(3y)27.91%
ROA(5y)18.35%
ROE(3y)41.42%
ROE(5y)28.93%
ROIC(3y)38.31%
ROIC(5y)29.36%
HME.CA Yearly ROA, ROE, ROICHME.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • HME has a Profit Margin of 30.81%. This is amongst the best in the industry. HME outperforms 96.19% of its industry peers.
  • HME's Profit Margin has improved in the last couple of years.
  • HME's Operating Margin of 42.73% is amongst the best of the industry. HME outperforms 92.86% of its industry peers.
  • In the last couple of years the Operating Margin of HME has grown nicely.
  • Looking at the Gross Margin, with a value of 60.82%, HME is in the better half of the industry, outperforming 79.05% of the companies in the same industry.
  • In the last couple of years the Gross Margin of HME has remained more or less at the same level.
Industry RankSector Rank
OM 42.73%
PM (TTM) 30.81%
GM 60.82%
OM growth 3Y2.1%
OM growth 5Y4.69%
PM growth 3Y34.16%
PM growth 5Y45.92%
GM growth 3Y-1.38%
GM growth 5Y-1.19%
HME.CA Yearly Profit, Operating, Gross MarginsHME.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

8

2. HME.CA Health Analysis

2.1 Basic Checks

  • HME has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • HME has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HME has more shares outstanding
  • HME has a better debt/assets ratio than last year.
HME.CA Yearly Shares OutstandingHME.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HME.CA Yearly Total Debt VS Total AssetsHME.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 5.91 indicates that HME is not in any danger for bankruptcy at the moment.
  • HME's Altman-Z score of 5.91 is amongst the best of the industry. HME outperforms 85.71% of its industry peers.
  • HME has a debt to FCF ratio of 0.07. This is a very positive value and a sign of high solvency as it would only need 0.07 years to pay back of all of its debts.
  • HME's Debt to FCF ratio of 0.07 is amongst the best of the industry. HME outperforms 96.67% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that HME is not too dependend on debt financing.
  • The Debt to Equity ratio of HME (0.03) is better than 76.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.07
Altman-Z 5.91
ROIC/WACC4.02
WACC7.96%
HME.CA Yearly LT Debt VS Equity VS FCFHME.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.41 indicates that HME should not have too much problems paying its short term obligations.
  • HME has a better Current ratio (1.41) than 70.00% of its industry peers.
  • A Quick Ratio of 1.41 indicates that HME should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.41, HME is in the better half of the industry, outperforming 70.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
HME.CA Yearly Current Assets VS Current LiabilitesHME.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

3

3. HME.CA Growth Analysis

3.1 Past

  • The earnings per share for HME have decreased by -9.09% in the last year.
  • HME shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 80.04% yearly.
  • The Revenue has decreased by -0.77% in the past year.
  • HME shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.97% yearly.
EPS 1Y (TTM)-9.09%
EPS 3Y72.84%
EPS 5Y80.04%
EPS Q2Q%-22.22%
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y32.32%
Revenue growth 5Y25.97%
Sales Q2Q%-13.24%

3.2 Future

  • HME is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.87% yearly.
  • The Revenue is expected to decrease by -7.01% on average over the next years.
EPS Next Y-12.61%
EPS Next 2Y-7.35%
EPS Next 3Y-6.72%
EPS Next 5Y-15.87%
Revenue Next Year-6.03%
Revenue Next 2Y-7.66%
Revenue Next 3Y-4.8%
Revenue Next 5Y-7.01%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HME.CA Yearly Revenue VS EstimatesHME.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
HME.CA Yearly EPS VS EstimatesHME.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2022 2023 2024 2025 2026 2027 2028 0 0.1 0.2 0.3

7

4. HME.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.47 indicates a reasonable valuation of HME.
  • 82.38% of the companies in the same industry are more expensive than HME, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.91. HME is valued rather cheaply when compared to this.
  • With a Price/Forward Earnings ratio of 10.03, the valuation of HME can be described as very reasonable.
  • 79.05% of the companies in the same industry are more expensive than HME, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of HME to the average of the S&P500 Index (23.69), we can say HME is valued rather cheaply.
Industry RankSector Rank
PE 9.47
Fwd PE 10.03
HME.CA Price Earnings VS Forward Price EarningsHME.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HME indicates a rather cheap valuation: HME is cheaper than 90.48% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HME indicates a rather cheap valuation: HME is cheaper than 92.86% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.13
EV/EBITDA 4.6
HME.CA Per share dataHME.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • HME has an outstanding profitability rating, which may justify a higher PE ratio.
  • HME's earnings are expected to decrease with -6.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-7.35%
EPS Next 3Y-6.72%

4

5. HME.CA Dividend Analysis

5.1 Amount

  • HME has a Yearly Dividend Yield of 3.47%.
  • Compared to an average industry Dividend Yield of 4.07, HME pays a bit more dividend than its industry peers.
  • HME's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 3.47%

5.2 History

  • HME has been paying a dividend for over 5 years, so it has already some track record.
  • HME has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
HME.CA Yearly Dividends per shareHME.CA Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 60.59% of the earnings are spent on dividend by HME. This is not a sustainable payout ratio.
DP60.59%
EPS Next 2Y-7.35%
EPS Next 3Y-6.72%
HME.CA Yearly Income VS Free CF VS DividendHME.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M
HME.CA Dividend Payout.HME.CA Dividend Payout, showing the Payout Ratio.HME.CA Dividend Payout.PayoutRetained Earnings

HME.CA Fundamentals: All Metrics, Ratios and Statistics

HEMISPHERE ENERGY CORP

TSX-V:HME (4/7/2026, 7:00:00 PM)

2.84

+0.02 (+0.71%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)11-25
Earnings (Next)04-15
Inst Owners0.94%
Inst Owner ChangeN/A
Ins Owners16.08%
Ins Owner ChangeN/A
Market Cap267.90M
Revenue(TTM)98.24M
Net Income(TTM)30.27M
Analysts84.44
Price Target2.96 (4.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.47%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP60.59%
Div Incr Years0
Div Non Decr Years3
Ex-Date04-15
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.91%
Min EPS beat(2)-2.91%
Max EPS beat(2)-2.91%
EPS beat(4)1
Avg EPS beat(4)-1.48%
Min EPS beat(4)-2.91%
Max EPS beat(4)2.8%
EPS beat(8)3
Avg EPS beat(8)-2.87%
EPS beat(12)5
Avg EPS beat(12)1.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.89%
Min Revenue beat(2)-0.21%
Max Revenue beat(2)5.99%
Revenue beat(4)3
Avg Revenue beat(4)2.9%
Min Revenue beat(4)-0.21%
Max Revenue beat(4)5.99%
Revenue beat(8)5
Avg Revenue beat(8)0.35%
Revenue beat(12)7
Avg Revenue beat(12)-0.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.73%
PT rev (3m)19.59%
EPS NQ rev (1m)20%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)1.82%
Revenue NQ rev (1m)2.45%
Revenue NQ rev (3m)2.29%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE 9.47
Fwd PE 10.03
P/S 2.73
P/FCF 6.13
P/OCF 4.82
P/B 3.39
P/tB 3.39
EV/EBITDA 4.6
EPS(TTM)0.3
EY10.56%
EPS(NY)0.28
Fwd EY9.97%
FCF(TTM)0.46
FCFY16.31%
OCF(TTM)0.59
OCFY20.75%
SpS1.04
BVpS0.84
TBVpS0.84
PEG (NY)N/A
PEG (5Y)0.12
Graham Number2.38
Profitability
Industry RankSector Rank
ROA 24.66%
ROE 38.33%
ROCE 42.48%
ROIC 31.98%
ROICexc 43.34%
ROICexgc 43.34%
OM 42.73%
PM (TTM) 30.81%
GM 60.82%
FCFM 44.47%
ROA(3y)27.91%
ROA(5y)18.35%
ROE(3y)41.42%
ROE(5y)28.93%
ROIC(3y)38.31%
ROIC(5y)29.36%
ROICexc(3y)41.04%
ROICexc(5y)31.02%
ROICexgc(3y)41.04%
ROICexgc(5y)31.02%
ROCE(3y)50.88%
ROCE(5y)39%
ROICexgc growth 3Y12.92%
ROICexgc growth 5Y20.01%
ROICexc growth 3Y12.92%
ROICexc growth 5Y20.01%
OM growth 3Y2.1%
OM growth 5Y4.69%
PM growth 3Y34.16%
PM growth 5Y45.92%
GM growth 3Y-1.38%
GM growth 5Y-1.19%
F-Score6
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.07
Debt/EBITDA 0.04
Cap/Depr 105.19%
Cap/Sales 12.1%
Interest Coverage 250
Cash Conversion 104.31%
Profit Quality 144.34%
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z 5.91
F-Score6
WACC7.96%
ROIC/WACC4.02
Cap/Depr(3y)210.69%
Cap/Depr(5y)187.35%
Cap/Sales(3y)20.24%
Cap/Sales(5y)19.51%
Profit Quality(3y)104.52%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.09%
EPS 3Y72.84%
EPS 5Y80.04%
EPS Q2Q%-22.22%
EPS Next Y-12.61%
EPS Next 2Y-7.35%
EPS Next 3Y-6.72%
EPS Next 5Y-15.87%
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y32.32%
Revenue growth 5Y25.97%
Sales Q2Q%-13.24%
Revenue Next Year-6.03%
Revenue Next 2Y-7.66%
Revenue Next 3Y-4.8%
Revenue Next 5Y-7.01%
EBIT growth 1Y-3.75%
EBIT growth 3Y35.09%
EBIT growth 5Y31.88%
EBIT Next Year34.08%
EBIT Next 3Y-0.98%
EBIT Next 5Y-5.77%
FCF growth 1Y130.83%
FCF growth 3Y57.01%
FCF growth 5YN/A
OCF growth 1Y39.86%
OCF growth 3Y36.33%
OCF growth 5Y34.82%

HEMISPHERE ENERGY CORP / HME.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HEMISPHERE ENERGY CORP (HME.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to HME.CA.


What is the valuation status for HME stock?

ChartMill assigns a valuation rating of 7 / 10 to HEMISPHERE ENERGY CORP (HME.CA). This can be considered as Undervalued.


What is the profitability of HME stock?

HEMISPHERE ENERGY CORP (HME.CA) has a profitability rating of 9 / 10.


Can you provide the financial health for HME stock?

The financial health rating of HEMISPHERE ENERGY CORP (HME.CA) is 8 / 10.


What is the earnings growth outlook for HEMISPHERE ENERGY CORP?

The Earnings per Share (EPS) of HEMISPHERE ENERGY CORP (HME.CA) is expected to decline by -12.61% in the next year.